NASDAQ:SERA Sera Prognostics (SERA) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free SERA Stock Alerts $9.10 -0.36 (-3.81%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$8.58▼$9.5050-Day Range$5.81▼$10.0052-Week Range$1.52▼$10.44Volume954,568 shsAverage Volume250,452 shsMarket Capitalization$285.19 millionP/E RatioN/ADividend YieldN/APrice Target$2.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Sera Prognostics alerts: Email Address Sera Prognostics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside69.8% Downside$2.75 Price TargetShort InterestHealthy0.68% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.54Based on 20 Articles This WeekInsider TradingSelling Shares$1.03 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.94) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.65 out of 5 starsMedical Sector867th out of 938 stocksMedical Laboratories Industry20th out of 20 stocks 1.3 Analyst's Opinion Consensus RatingSera Prognostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.75, Sera Prognostics has a forecasted downside of 69.8% from its current price of $9.12.Amount of Analyst CoverageSera Prognostics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.68% of the float of Sera Prognostics has been sold short.Short Interest Ratio / Days to CoverSera Prognostics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sera Prognostics has recently increased by 8.63%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSera Prognostics does not currently pay a dividend.Dividend GrowthSera Prognostics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SERA. Previous Next 2.5 News and Social Media Coverage News SentimentSera Prognostics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Sera Prognostics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for SERA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows5 people have added Sera Prognostics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sera Prognostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,033,948.00 in company stock.Percentage Held by Insiders15.60% of the stock of Sera Prognostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.64% of the stock of Sera Prognostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sera Prognostics are expected to grow in the coming year, from ($0.94) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sera Prognostics is -7.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sera Prognostics is -7.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSera Prognostics has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Sera Prognostics Stock (NASDAQ:SERA)Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.Read More SERA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SERA Stock News HeadlinesMarch 27, 2024 | insidertrades.comSera Prognostics, Inc. (NASDAQ:SERA) CFO Sells $75,822.04 in StockMarch 27, 2024 | finance.yahoo.comChief Scientific Officer John Boniface Sells 21,438 Shares of Sera Prognostics Inc (SERA)March 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 27, 2024 | finance.yahoo.comChief Scientific Officer John Boniface Sells 22,163 Shares of Sera Prognostics Inc (SERA)March 27, 2024 | americanbankingnews.comSera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts Sells 8,092 SharesMarch 27, 2024 | americanbankingnews.comSera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt Sells 38,899 Shares of StockMarch 27, 2024 | americanbankingnews.comSera Prognostics, Inc. (NASDAQ:SERA) Insider John J. Boniface Sells 21,438 Shares of StockMarch 25, 2024 | americanbankingnews.comWilliam Blair Comments on Sera Prognostics, Inc.'s Q1 2024 Earnings (NASDAQ:SERA)March 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 23, 2024 | americanbankingnews.comSera Prognostics, Inc. Forecasted to Post Q1 2025 Earnings of ($0.26) Per Share (NASDAQ:SERA)March 21, 2024 | finanznachrichten.deSera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2023 Financial ResultsMarch 21, 2024 | finance.yahoo.comSera Prognostics, Inc. (NASDAQ:SERA) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | investorplace.comSERA Stock Earnings: Sera Prognostics Beats EPS, Misses Revenue for Q4 2023March 20, 2024 | benzinga.comSera Prognostics: Q4 Earnings InsightsMarch 20, 2024 | finance.yahoo.comSERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTSMarch 20, 2024 | finance.yahoo.comSera Prognostics Inc Reports Modest Revenue Growth Amid Operational StreamliningMarch 19, 2024 | benzinga.comSera Prognostics's Earnings OutlookMarch 19, 2024 | markets.businessinsider.comSera Prognostics A is about to announce its earnings — here's what to expectMarch 19, 2024 | finance.yahoo.comCompanies Like Sera Prognostics (NASDAQ:SERA) Are In A Position To Invest In GrowthMarch 4, 2024 | prnewswire.comSera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2023 Financial Results on March 20, 2024February 29, 2024 | prnewswire.comSera Prognostics To Present at TD Cowen 44th Annual Healthcare ConferenceFebruary 22, 2024 | benzinga.comSera Prognostics Stock (NASDAQ:SERA), Short Interest ReportFebruary 15, 2024 | msn.comTop Growth Stocks Under $50 for February 2024January 11, 2024 | msn.comSera Prognostics, Atreca spike after Baker Bros investmentsJanuary 4, 2024 | finance.yahoo.comPRISM MarketView Launches Emerging Women’s Health IndexJanuary 3, 2024 | finance.yahoo.comEarlyDiagnostics, Inc. Appoints Gregory C. Critchfield, M.D. M.S., as Co-CEODecember 11, 2023 | finance.yahoo.comHere's Why Sera Prognostics, Inc. (SERA) is a Great Momentum Stock to BuySee More Headlines Receive SERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sera Prognostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/28/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:SERA CUSIPN/A CIK1534969 Webwww.seraprognostics.com Phone801-990-0520FaxN/AEmployees87Year FoundedN/APrice Target and Rating Average Stock Price Target$2.75 High Stock Price Target$2.75 Low Stock Price Target$2.75 Potential Upside/Downside-70.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,240,000.00 Net Margins-11,843.79% Pretax Margin-11,843.79% Return on Equity-45.74% Return on Assets-37.38% Debt Debt-to-Equity RatioN/A Current Ratio2.51 Quick Ratio2.51 Sales & Book Value Annual Sales$310,000.00 Price / Sales956.38 Cash FlowN/A Price / Cash FlowN/A Book Value$2.24 per share Price / Book4.22Miscellaneous Outstanding Shares31,340,000Free Float26,448,000Market Cap$296.48 million OptionableNot Optionable Beta1.51 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMs. Evguenia Lindgardt M.B.A. (Age 50)President, CEO & Director Comp: $37.5kDr. Gregory C. Critchfield M.D. (Age 71)M.S., Executive Director Comp: $790.74kDr. Steven W. GravesCo-Founder and Co-Chairman of The Scientific Advisory BoardDr. M. Sean Esplin M.D.Co-Founder and Co-Chairman of Scientific Advisory BoardMr. Austin AertsChief Financial Officer??Dr. John J. Boniface Ph.D. (Age 62)Chief Scientific Officer Comp: $386.69kMr. Robert G. Harrison (Age 58)Chief Information Officer Comp: $384.18kMr. Benjamin G. Jackson J.D. (Age 45)General Counsel Comp: $410.75kDr. Paul Kearney Ph.D. (Age 56)Chief Data Officer More ExecutivesKey CompetitorsCelcuityNASDAQ:CELCHH&L AcquisitionNYSE:HHLABiodesixNASDAQ:BDSXGenetronNASDAQ:GTHCareDxNASDAQ:CDNAView All CompetitorsInsiders & InstitutionsZhenya LindgardtSold 38,899 sharesTotal: $364,483.63 ($9.37/share)Austin AertsSold 8,092 sharesTotal: $75,822.04 ($9.37/share)John J BonifaceSold 21,438 sharesTotal: $204,732.90 ($9.55/share)Vanguard Group Inc.Bought 122,710 shares on 3/11/2024Ownership: 2.902%Price T Rowe Associates Inc. MDBought 151,933 shares on 2/16/2024Ownership: 0.485%View All Insider TransactionsView All Institutional Transactions SERA Stock Analysis - Frequently Asked Questions Should I buy or sell Sera Prognostics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sera Prognostics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SERA shares. View SERA analyst ratings or view top-rated stocks. What is Sera Prognostics' stock price target for 2024? 2 equities research analysts have issued 12-month target prices for Sera Prognostics' stock. Their SERA share price targets range from $2.75 to $2.75. On average, they anticipate the company's stock price to reach $2.75 in the next twelve months. This suggests that the stock has a possible downside of 69.8%. View analysts price targets for SERA or view top-rated stocks among Wall Street analysts. How have SERA shares performed in 2024? Sera Prognostics' stock was trading at $5.98 at the beginning of the year. Since then, SERA shares have increased by 52.5% and is now trading at $9.12. View the best growth stocks for 2024 here. When is Sera Prognostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our SERA earnings forecast. How were Sera Prognostics' earnings last quarter? Sera Prognostics, Inc. (NASDAQ:SERA) released its earnings results on Tuesday, November, 9th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.17. The business earned $0.02 million during the quarter, compared to analyst estimates of $0.08 million. Sera Prognostics had a negative trailing twelve-month return on equity of 45.74% and a negative net margin of 11,843.79%. When did Sera Prognostics IPO? Sera Prognostics (SERA) raised $75 million in an initial public offering (IPO) on Thursday, July 15th 2021. The company issued 4,687,500 shares at a price of $15.00-$17.00 per share. Who are Sera Prognostics' major shareholders? Sera Prognostics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (5.27%), Vanguard Group Inc. (2.90%), Vanguard Group Inc. (2.90%), Price T Rowe Associates Inc. MD (0.48%), Price T Rowe Associates Inc. MD (0.48%) and Acuitas Investments LLC (0.39%). Insiders that own company stock include Austin Aerts, Benjamin Jackson, John J Boniface, Paul Kearney, Robert Gardner Harrison and Zhenya Lindgardt. View institutional ownership trends. How do I buy shares of Sera Prognostics? Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SERA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry ResearchSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sera Prognostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.